Back to All Case Studies

Driving Innovations in STING Technology for Cancer Immunotherapy

InfinixBio partnered with a biotech company developing a microbial-based, tumor-targeting immunotherapy platform for solid tumors.

Client’s Goals:

The aim was to develop a platform capable of safely delivering therapeutic agents directly to the tumor microenvironment to stimulate an immune response.

Challenges Faced:

The client needed a live bacterial strain capable of tissue-specific localization and enrichment, delivered via systemic administration with enhanced safety.

Solutions Provided by InfinixBio:

Using our expertise in bacterial strain engineering:

• Precision genome editing was used to tailor the bacterial strain for therapeutic needs.
• Ensured the modified strain met all specifications for effective delivery.

Results:

Our genetic modifications allowed the client to utilize resources effectively and reduce development risks, leading to a Phase 1 clinical trial of their lead drug candidate.

Driving Innovations in STING Technology for Cancer Immunotherapy

In the heart of biotech innovation, InfinixBio forged a groundbreaking partnership with a visionary company dedicated to advancing cancer treatment. This biotech company was on a mission to develop a microbial-based, tumor-targeting immunotherapy platform designed to combat solid tumors.

Their ambitious goal was to create a platform that could safely and effectively deliver therapeutic agents directly into the tumor microenvironment, thereby stimulating a robust immune response.

The client faced a significant challenge: they needed a live bacterial strain that could specifically localize and enrich within tumor tissues. This strain had to be delivered systemically, ensuring it could navigate the complexities of the human body and reach its target with enhanced safety.

InfinixBio’s expertise in bacterial strain engineering became invaluable.

• Our team embarked on a journey to develop a bacterial strain precisely tailored for this innovative immunotherapy platform.
• Through precision genome editing, we meticulously engineered the strain to meet the therapeutic needs.
• Ensured the strain could deliver therapeutic agents directly to the tumor with pinpoint accuracy.

Our rigorous genetic modifications were not just about precision; they were about meeting stringent safety and efficacy specifications. Each modification was carefully tested and validated to ensure the bacterial strain could effectively localize to tumor tissues and deliver its therapeutic payload without compromising patient safety.

This collaboration bore fruit, allowing the client to utilize their resources more effectively and significantly reduce development risks. The result was a major milestone: the lead drug candidate advanced to a Phase 1 clinical trial, marking a significant step forward in the fight against cancer.

Through this partnership, InfinixBio demonstrated the power of innovation and collaboration in driving forward the next generation of cancer immunotherapy. This journey not only showcased our capabilities in bacterial strain engineering but also highlighted the potential of microbial-based therapies to revolutionize cancer treatment.